What is the typical dosage and treatment duration for Cipro (ciprofloxacin) in bacterial infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ciprofloxacin Dosing for Bacterial Infections

For most bacterial infections, ciprofloxacin is dosed at 500 mg orally twice daily, with duration and dose adjustments based on infection severity and site: 250 mg twice daily for uncomplicated UTIs (3-7 days), 500 mg twice daily for moderate infections (7-14 days), and 750 mg twice daily for severe/complicated infections (7-14 days to 6 weeks depending on site). 1

Standard Dosing by Infection Type

Urinary Tract Infections

  • Uncomplicated cystitis: 250 mg orally twice daily for 3 days (minimum effective dose) 2, though fluoroquinolones should be reserved as alternatives when other agents cannot be used 3
  • Complicated UTI/Pyelonephritis: 500 mg orally twice daily for 7 days 3, 1
  • Extended-release formulation: 1000 mg once daily for 7 days is equally effective as 500 mg twice daily 3, 4
  • Initial IV therapy option: 400 mg IV may be given before switching to oral therapy, particularly if local fluoroquinolone resistance exceeds 10% 3

Respiratory Tract Infections

  • Mild to moderate: 500 mg orally twice daily for 7-14 days 1
  • Severe/complicated: 750 mg orally twice daily for 7-14 days 1
  • Community-acquired pneumonia: 750 mg orally twice daily for 3-6 days, then 500 mg twice daily for 4-7 days has shown 100% success rates 5

Skin and Soft Tissue Infections

  • Mild to moderate: 500 mg orally twice daily for 7-14 days 1
  • Severe/complicated: 750 mg orally twice daily for 7-14 days 1
  • Bite wounds (animal/human): 500-750 mg orally twice daily 6

Bone and Joint Infections

  • All severities: 500 mg (mild/moderate) to 750 mg (severe) orally twice daily for ≥4-6 weeks 1

Gastrointestinal Infections

  • Infectious diarrhea: 500 mg orally twice daily for 5-7 days 1
  • Traveler's diarrhea (empiric): 500 mg orally twice daily for 3-7 days 6
  • Salmonella gastroenteritis in HIV patients: 750 mg orally twice daily for 14 days 6
  • Typhoid fever: 500 mg orally twice daily for 10 days 1

Inhalational Anthrax (Post-Exposure)

  • Adults: 500 mg orally twice daily for 60 days 6, 1
  • Children: 15 mg/kg (maximum 500 mg per dose) orally twice daily for 60 days 6, 1

Other Infections

  • Chronic bacterial prostatitis: 500 mg orally twice daily for 28 days 1
  • Acute sinusitis: 500 mg orally twice daily for 10 days 1
  • Intra-abdominal (complicated): 500 mg orally twice daily for 7-14 days 1
  • Uncomplicated gonorrhea: 250 mg single dose (though resistance now limits this use) 1

Pediatric Dosing

Fluoroquinolones should be used with extreme caution in children and only when no alternatives exist due to concerns about joint/cartilage toxicity. 6

  • Complicated UTI/Pyelonephritis:
    • IV: 6-10 mg/kg (maximum 400 mg) every 8 hours 1
    • Oral: 10-20 mg/kg (maximum 750 mg) every 12 hours 1
    • Duration: 10-21 days 1
  • Inhalational anthrax: 15 mg/kg (maximum 500 mg) orally every 12 hours for 60 days 6, 1
  • Maximum daily dose: Should not exceed 1 gram per day in children 6
  • Consultation recommended: Pediatric infectious diseases specialist consultation is suggested before using ciprofloxacin in children 6

Special Populations

Renal Impairment

Dosing adjustments are required based on creatinine clearance 1:

  • CrCl >50 mL/min: Standard dosing
  • CrCl 30-50 mL/min: 250-500 mg every 12 hours
  • CrCl 5-29 mL/min: 250-500 mg every 18 hours
  • Hemodialysis/peritoneal dialysis: 250-500 mg every 24 hours (after dialysis)
  • Severe infections with severe renal impairment: 750 mg may be used at the above intervals with careful monitoring 1

Pregnancy

Fluoroquinolones should be avoided during pregnancy. 6 However, for life-threatening infections (e.g., inhalational anthrax), ciprofloxacin may be used as the risk of infection outweighs drug risks 6. Adverse effects on developing teeth and bones are dose-related, so short-term use (7-14 days) before six months of gestation may be considered for serious infections 6.

HIV-Infected Patients

  • Traveler's diarrhea prophylaxis: 500 mg orally once daily when prophylaxis is deemed necessary 6
  • Salmonella gastroenteritis treatment: 750 mg orally twice daily for 14 days to prevent extraintestinal spread 6

IV to Oral Conversion

Patients may be switched from IV to oral therapy when clinically appropriate 1:

  • 200 mg IV every 12 hours = 250 mg oral every 12 hours
  • 400 mg IV every 12 hours = 500 mg oral every 12 hours
  • 400 mg IV every 8 hours = 750 mg oral every 12 hours

Sequential IV/oral therapy is as effective as continuous IV therapy and allows earlier hospital discharge 7.

Critical Clinical Considerations

Resistance Patterns

  • Obtain cultures before initiating therapy for pyelonephritis and serious infections 3
  • If local fluoroquinolone resistance exceeds 10%, administer an initial long-acting parenteral antimicrobial before starting oral ciprofloxacin 3
  • Reserve fluoroquinolones for situations where other antimicrobials cannot be used for uncomplicated cystitis due to resistance concerns 3

Drug Interactions

  • Separate from multivalent cations: Take ciprofloxacin at least 1-2 hours before, or 4 hours after, antacids, calcium, or aluminum-containing preparations 6
  • Monitor anticoagulation: Enhanced effects of warfarin and other vitamin K antagonists 6
  • QT prolongation risk: Baseline ECG, repeat at 2 weeks and after adding any QT-prolonging medications 6

Common Pitfalls

  • Pneumonia failures: Most treatment failures occur with pneumonia (2 of 5 ciprofloxacin failures in one study) 7
  • Meningitis: Doxycycline may be preferred over ciprofloxacin for CNS infections due to better penetration 6
  • Enterococcal coverage: Ciprofloxacin lacks reliable enterococcal activity; consider alternative agents for suspected enterococcal infections 7
  • Fungal superinfections: Occur in 26% of patients, most commonly genitourinary with indwelling catheters 7

Monitoring

  • Blood glucose: Monitor regularly in diabetic patients (risk of hypoglycemia) 6
  • Serum levels: Target trough 1-1.5 mg/L, peak 3-4.5 mg/L (for 500-750 mg twice daily dosing) 6
  • Routine toxicity: Intermittent CBC, renal function, and liver function tests throughout treatment 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.